Provided by Healio
October 18, 2013
BRUSSELS — Peter Reiss, MD, PhD, professor of medicine at the University of Amsterdam, discusses the ongoing development of direct-acting antivirals, which is expected by many physicians to revolutionize the treatment of HIV and hepatitis C virus co-infections.
During a plenary session at EACS 2013, presenter Heinrich Wedemeyer, MD, from the Hannover Medical School, described the advent of direct-acting antiviral agents as a revolution in treatment for chronic HCV, but also cited several remaining challenges, namely drug interactions and cost.
No comments:
Post a Comment